Perioperative Treatment of Resectable Liver Metastases

Phase 2 Withdrawn University of Regensburg University of Halle Medical Faculty · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized, controlled, multicenter, non-comparative phase II trial compares an intensified perioperative treatment of patients with resectable synchronous or metachronous colorectal liver metastases to primary surgery and adjuvant systemic chemotherapy.

Timeline

Start: 2012-09
Primary completion: 2013-05
Completion: 2013-05

Outcome

Outcome not reported

Stopped (Enrollment): “insufficient recruitment”

Publications

Background Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Konigsrainer A, Richter M, Schlitt HJ, Schmoll HJ. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer. 2012 Aug 16;12:356. doi: 10.1186/1471-2407-12-356.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous